October 23, 2017 / 6:17 AM / a month ago

BRIEF-AstraZeneca gains FDA backing for Bydureon BCise

Oct 23 (Reuters) - AstraZeneca Plc

* ‍US FDA approves new easy-to-use, once-weekly Bydureon BCise injectable medicine for patients with type-2 diabetes​

* ‍Bydureon BCise will be available for patients in US in Q1 of 2018​

* ‍a regulatory application for new autoinjector device has also been accepted by european medicines agency​ Source text for Eikon: Further company coverage: (London newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below